Will $2.5Bn Jury Verdict Against Gilead Stand? Future Royalties, Willful Infringement Penalty Uncertain
Executive Summary
Gilead is appealing a jury finding that it must pay Merck 10% royalty on sales of Sovaldi and Harvoni through August 2016; judge could find the firm owes treble the amount for willful infringement.
You may also be interested in...
Biogen Pays $1.25bn For Peace Of Mind Over Tecfidera, But Legal Wrangling Continues
Biogen's new CEO Michel Vounatsos has begun his tenure by taking out a $1.25bn "insurance policy" on MS drug Tecfidera by licensing Forward Pharma's patent portfolio, but the cost of the deal could spiral if the Danish firm wins a series of ongoing patent disputes with Biogen concerning Tecfidera and Forward Pharma's MS drug candidate FP187.
HCV Patent Case: With "Unclean Hands," Merck Can't Collect Jury Award From Gilead
Gilead scored a victory in its patent dispute with Merck, in which the latter company was accused by a federal judge of egregious misconduct and being guilty of "unclean hands," and therefore, could not collect the $200m jury award the company had earlier won.
Merck Gets $200m In Gilead Patent Case, But Who Wins?
A jury in the US District Court for the Northern District of California, which decided earlier in the week that Gilead Sciences Inc. infringed two of Merck & Co. Inc.'s hepatitis C drug patents, determined on March 24 that Gilead should pay its rival $200m – a sum much lower than what Merck sought when the companies' patent dispute began in 2013.